Article Text

Download PDFPDF
New therapies for clear cell ovarian carcinoma
  1. James Stewart1,2,
  2. Niamh Cunningham1 and
  3. Susana Banerjee1,3
  1. 1 Royal Marsden Hospital NHS Trust, London, UK
  2. 2 Gene Function Laboratory, Insitute of Cancer Research, London, UK
  3. 3 Division of Clinical Studies, Institute of Cancer Research, London, UK
  1. Correspondence to Dr Susana Banerjee, Royal Marsden NHS Foundation Trust, London, SW3 6JJ, UK; susana.banerjee{at}


Ovarian clear cell carcinoma is a rare subtype of epithelial ovarian cancer with unique clinicopathological features. The most common genetic aberration observed is loss of function ARID1A mutations. Advanced and recurrent ovarian clear cell carcinoma is characterized by resistance to standard-of-care cytotoxic chemotherapy and a poor prognosis. Despite the distinct molecular features of ovarian clear cell carcinoma, current treatments for this subtype of epithelial ovarian cancer are based on clinical trials which predominantly recruited patients with high grade serous ovarian carcinoma. These factors have encouraged researchers to develop novel treatment strategies specifically for ovarian clear cell carcinoma which are currently being tested in the context of clinical trials. These new treatment strategies currently focus on three key areas: immune checkpoint blockade, targeting angiogenesis, and exploiting ARID1A synthetic lethal interactions. Rational combinations of these strategies are being assessed in clinical trials. Despite the progress made in identifying new treatments for ovarian clear cell carcinoma, predictive biomarkers to better define those patients likely to respond to new treatments remain to be elucidated. Additional future challenges which may be addressed through international collaboration include the need for randomized trials in a rare disease and establishing the relative sequencing of these novel treatments.

  • Ovarian Cancer

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors All co-authors contributed in planning, writing and reviewing. In addition S Banerjee supervised the preparation of the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests SB: Research Grants: AstraZeneca, GlaxoSmithKline; Advisory Boards: Amgen, AstraZeneca, Epsilogen, GlaxoSmithKline Immunogen, Merck Sharpe Dohme, Merck Sereno, Mersana, Novartis, Oncxerna, Regeneron, Seagen, Shattuck Labs; Honoraria for lectures: Amgen, AstraZeneca, Clovis, GlaxoSmithKine, Immunogen, Merck Sharpe Dohme, Mersana, Pfizer, Roche, Takeda. NC: No disclosures. JS: No disclosures.

  • Provenance and peer review Commissioned; internally peer reviewed.